#USA #Beijing #Allink Biotherapeutics #Lanchi Ventures #ADC technology

A Major Financial Boost for Allink Biotherapeutics

Allink Biotherapeutics, a cutting-edge clinical-stage biotechnology firm, has recently completed a successful Series A financing round amounting to $42 million, led by Lanchi Ventures. This pivotal funding aims to fuel the rapid advancement of the company's bispecific antibody and antibody-drug conjugate (ADC) portfolio.

The funding round witnessed participation from esteemed investors such as Yuanbio Venture Capital, Legend Capital, and CD Emerging Industry Equity Investment, alongside ongoing backing from existing stakeholders like Gaorong Ventures and Med-Fine Capital. The infusion of capital is set to expedite Allink's entry into Phase I/II clinical trials, showcasing their commitment to pushing boundaries in biotechnology.

Hui Feng, Ph.D., the visionary founder and CEO of Allink Biotherapeutics, expressed gratitude for both new and existing investors who share a vision for scientific innovation. Under his leadership, the firm has quickly transitioned from its founding phase to clinical development within just over a year. Dr. Feng emphasized that this financial backing enables the acceleration of their diverse therapeutic pipeline that targets significant unmet medical needs in oncology and immunology.

Beyond advancing pivotal therapies like ALK201 and ALK202, the funds will also allow the company to enhance its proprietary bispecific antibody and ADC technology platform. This will ensure that Allink not only keeps pace with advancements in the field but also leads transformative changes in treatment modalities.

As highlighted by Lanchi Ventures, Allink's swift progress in clinical trials evidences its competitive stance within China's burgeoning biopharmaceutical sector. The investment firm acknowledged Dr. Feng's leadership, stating that it illustrates the potential of Allink’s innovative approach.

Once initiated, the clinical development will span multiple global locations, including Australia, the USA, and China, thus expanding Allink's reach on an international scale. The company's goal is to position itself prominently within the targeted oncology therapeutics market, catering to urgent therapeutic needs for patients worldwide.

In summary, the successful completion of this funding round marks a significant turning point for Allink Biotherapeutics. With secure financial resources and a robust R&D framework, the company is set to achieve remarkable milestones in its journey towards delivering innovative therapies. Their ambition to revolutionize treatment options stands at the forefront of its mission, promising considerable advancements in addressing critical health challenges on a global level.

About Allink Biotherapeutics

Founded in 2023, Allink Biotherapeutics leverages proprietary platforms in bispecific antibodies and ADCs to create a diverse pipeline of First-in-Class and Best-in-Class therapeutics aimed at treating oncology and immunology diseases. The firm is dedicated to bridging the gaps in medical care by investigating and developing highly effective drugs to meet critical patient needs.

About Lanchi Ventures

Lanchi Ventures has established itself as a prominent venture capital firm specializing in early-stage investments, with a strategic focus on technology-driven enterprises that aspire to create a positive impact. Its offices span across major regions including Singapore, Hong Kong, and Beijing, indicating a robust international presence. With an impressive portfolio valued at over $2 billion and more than 200 companies under its belt, Lanchi is recognized across various reputable platforms for its contributions to the tech and biotech sectors.